Literature DB >> 12827046

Penetrating keratoplasty in young children with congenital hereditary endothelial dystrophy.

Mohammad Ali Javadi1, Ali Reza Baradaran-Rafii, Mitra Zamani, Farid Karimian, Mohammad Zare, Bahram Einollahi, Mohammad Reza Jafarinasab, Shahin Yazdani.   

Abstract

PURPOSE: To report the visual results and success rate of penetrating keratoplasty (PKP) in a series of young children with congenital hereditary endothelial dystrophy (CHED).
METHODS: This is a retrospective study on twenty-four eyes of 15 patients (seven male and eight female) operated on for CHED. Children less than 12 years of age at the time of surgery who were followed for at least 6 months were recalled. Characteristics of the patients, indications for PKP, final visual outcome, and graft clarity were evaluated. The following tests were employed: McNemmar test for evaluating visual results, Kaplan-Meyer analysis for determination of graft survival, and Mann-Whitney U test for evaluating the relationship between visual outcome and age at PKP.
RESULTS: Patients' age at diagnosis and at initial PKP was 6.5 +/- 3.6 and 8.1 +/- 2.5 years, respectively. Follow-up period was 35.5 +/- 36.2 months. Visual acuity could be evaluated by Snellen chart in 19 eyes. Preoperative visual acuity was less than 20/80 in all of these. Postoperatively, visual acuity was less than 20/80 in nine eyes (47.4%) (P < 0.002). Visual acuity improved in 18 (94.7%) of 19 eyes. There was no relationship between age at initial PKP and final visual outcome (P = 0.35). At the last examination (24 grafts), 19 were clear (79.1%), two were hazy (8.3%), and three were opaque (12.5%). Allograft rejection was seen in 10 eyes (43.4%), seven of which were endothelial. Excluding one case of trauma, all graft failures resulted from endothelial rejection. The probability of primary graft survival was 88% at 3 years and 74% at 5 years.
CONCLUSION: Regarding the difficulties in pediatric keratoplasty and the absence of a relationship between postoperative visual outcome and age at keratoplasty, a conservative approach and careful risk-benefit ratio evaluation are recommended in patients with CHED.

Entities:  

Mesh:

Year:  2003        PMID: 12827046     DOI: 10.1097/00003226-200307000-00006

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  6 in total

1.  Successful Descemet's stripping automated endothelial keratoplasty for congenital hereditary endothelial dystrophy in a pediatric patient.

Authors:  Jeffrey M Goshe; Jennifer Y Li; Mark A Terry
Journal:  Int Ophthalmol       Date:  2012-01-25       Impact factor: 2.031

Review 2.  The challenging management of pediatric corneal transplantation: an overview of surgical and clinical experiences.

Authors:  Antonio Di Zazzo; Stefano Bonini; Salvatore Crugliano; Michele Fortunato
Journal:  Jpn J Ophthalmol       Date:  2017-04-03       Impact factor: 2.447

3.  Descemet's stripping endothelial keratoplasty (DSEK) for children with congenital hereditary endothelial dystrophy: surgical challenges and 1-year outcomes.

Authors:  Jatin N Ashar; K Madhavi Latha; Pravin K Vaddavalli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-19       Impact factor: 3.117

4.  Graft rejection in pediatric penetrating keratoplasty: Clinical features and outcomes.

Authors:  Rakhi Kusumesh; Murugesan Vanathi
Journal:  Oman J Ophthalmol       Date:  2015 Jan-Apr

5.  Eye Bank Records on Pediatric Keratoplasty.

Authors:  Seyed Mohamadmehdi Moshtaghion; Mohammad Abolhosseini; Bahareh Kheiri; Mohammad Ali Javadi; Leila Ziaee Ardakani; Mozhgan Rezaei Kanavi
Journal:  J Ophthalmic Vis Res       Date:  2022-08-15

6.  Microscope Integrated Optical Coherence Tomography Guided Descemet Stripping Automated Endothelial Keratoplasty in Congenital Hereditary Endothelial Dystrophy.

Authors:  Mohamed Ibrahime Asif; Rahul Kumar Bafna; Namrata Sharma; Ananya Kaginalkar; Rajesh Sinha; Tushar Agarwal; Prafulla Kumar Maharana; Manpreet Kaur; Priya Taank; Jeewan S Titiyal
Journal:  Clin Ophthalmol       Date:  2021-07-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.